Get started
Work

Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)

Year: 2013
Type: article
Study design: Clinical Trial
DOI: 10.1016/j.ejca.2013.10.006
Authors: J.R. Brahmer, J.W. Lee, A.M. Traynor, M.M. Hidalgo, J.M. Kolesar, J.M. Siegfried, P.P. Guaglianone, J.D. Patel, M.D. Keppen, J.H. Schiller
Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Dana-Farber Cancer Institute, University of Wisconsin–Madison, University of Pittsburgh, Decatur Memorial Hospital, Northwestern University, Sanford Health, The University of Texas Southwestern Medical Center
Language: English
Field: Medicine
Open Access status: green
Awards: ECOG Statistical Office Data Management Grant, G1422427855, Eastern Cooperative Oncology Group (Main Institution), G2017411191, ECOG - ACRIN CCOP RESEARCH BASE GRANT - CORE, Johns Hopkins University NCTN Lead Academic Site Program, Eastern Cooperative Oncology Group, ECOG Clinical Trials, G4412485521, G5733733469, G5765316850, G721629745, ECOG Specimen Banking, Johns Hopkins University NCTN Lead Academic Site Program, EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES, ECOG Statistical Office, Eastern Cooperative Oncology Group Operations Office, The Robert H. Lurie Comprehensive Cancer Center, Regional Oncology Research Center, G964706321
OpenAlex ID: W2045432173
FWCI: 3.53
Cites: 22
Cited by: 26
Related to: 10